



## Granules India Limited

11nd Floor, 3rd Block, My Home Hub, Madhapur, Hyderabad-500 081. INDIA  
Ph : +91-40-66760000, Fax : +91-40-2311514  
E-mail : mail@granulesindia.com URL : www.granulesindia.com

**Dated July 2, 2012**

The Manager  
Listing Department  
National Stock Exchange of India Limited  
'Exchange Plaza', C-1, Block G,  
Bandra-Kurla Complex, Bandra (E),  
Mumbai – 400 051

Fax: 022 – 26598237/38

Dear Sir,

**Sub: Press Release**

**Symbol: GRANULES**

Enclosed please find a Press Release titled “Granules India Announces Dividend Increase of 33%; second consecutive increase”.


Kindly take the above information on record

Thanking you,

Yours faithfully,

**FOR, GRANULES INDIA LIMITED**

  
(SHIVANGI SHARMA)  
Company Secretary &  
Compliance Officer



Encl: as above



## **Press Release**

### **Granules India Announces Dividend Increase of 33%; second consecutive increase**

**Hyderabad, July 2, 2012:** Granules India Ltd, a fast growing pharmaceutical manufacturing company, announced that shareholders approved a 33% increase in the dividend at its 21st Annual General Meeting. The dividend was increased to 20%, or Rs. 2.0 per share from Rs. 1.50 per share. This is the second consecutive year that Granules has increased its dividend.

"We increased our dividend due to the strong growth of our business. The increase in our dividend reflects the continued confidence we have in the performance of our business, future growth prospects, and our commitment to providing good return to our shareholders." said Krishna Prasad, Managing Director of Granules India.

The Company's consolidated net revenue increased by 38% to Rs. 654 Cr and net profit increased by 43% to Rs. 30 Cr for its fiscal year 2012 ended March 31, 2012. The Company expects the growth rate to increase in FY13 along with an improvement in profitability margins.

#### **About Granules India Ltd.**

(BSE: 532482, NSE: GRANULES)

Granules is a fast growing pharmaceutical manufacturing company with world class facilities and is committed to manufacturing excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets. Granules support customers with unique value, extensive product range, proactive solutions and a global network of associates. The Company's global presence extends to over 300 customers in 50 countries through offices in India, U.S., U.K., China and Colombia. Granules offer all three components of the pharmaceutical value chain which gives the customers flexibility and choice.

Granules has the largest PFI facility in the world with an industry leading 6 ton batch size. The Company has its own ANDAs and dossiers which enable customers to quickly enter a market instead of filing their own applications. Granules has a highly skilled regulatory affairs department that can offer customers support and can help them navigate through regulatory issues.

Granules has strengthened its advantages through its Operational Excellence (OE) department which looks at every step of the manufacturing process in order to gain efficiencies and has also implemented systems that have standardized quality and reduced variation. The Company's OE program is regularly cited by MNCs as a "best in class" program and is the comparative advantage that lets Granules provide world-class quality products at a lower cost than its competitors. The adoption of the OE philosophy by Granules has earned it several recognitions including The Economic Times Manufacturing Excellence Awards 2011.

#### **Caution Statement:**

Certain statements made above may be "forward looking statements" within the meaning of applicable laws and regulations.

#### **Contacts:**

Rukmini Baxi/ Divya Balasubramaniam  
Genesis Burson-Marsteller  
+91 964 232 0044/ +91 9962560024  
rukmini.baxi@bm.com/divya.bala@bm.com

**For GRANULES INDIA LIMITED**

  
**Company Secretary**

